Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows

With a stock price of $2.36, Caribou Biosciences, Inc. (NASDAQ:CRBU) is among the 8 Best Up and Coming Penny Stocks to Buy Now.

Caribou Biosciences, Inc. (NASDAQ:CRBU) attracted renewed attention after H.C. Wainwright analyst Robert Burns increased his price target on the stock to $11 from $9 on May 11 while maintaining a Buy rating following the company’s first-quarter results. The revised target reflects growing confidence in Caribou’s development pipeline and clinical progress, highlighting the potential value investors could realize if the company continues to execute on its strategic and operational objectives.

Earlier, on March 31, Caribou Biosciences, Inc. (NASDAQ:CRBU) announced that the U.S. Food and Drug Administration had granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for the treatment of relapsed or refractory multiple myeloma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy currently being evaluated in the ongoing Phase 1 CaMMouflage clinical trial. The RMAT designation is intended to expedite the development and review of promising regenerative medicine therapies and represents an important regulatory milestone that could help accelerate the program’s path toward commercialization.

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company headquartered in Berkeley, California, and was founded in 2011. The company focuses on developing next-generation, off-the-shelf CRISPR-edited cell therapies for patients with cancer and autoimmune diseases. The company completed its initial public offering in 2021.

READ NEXT: 10 Best Growth Stocks to Buy with Low P/E Ratios and 9 Best Space Stocks to Buy According to Reddit and Social Media.

Disclosure: None.  Follow Insider Monkey on Google News.